Où achat cialis sans ordonnance et acheter viagra en France.

Nagoya-biostat.jp

Nagoya University Graduate School of Medicine Education: Bachelor of Engineering, Dept. of Transportation Engineering, Tokyo Univ. of Sci., Master of Engineering, Dept. of Civil Engineering, Tokyo Univ. of Sci., 1993 Degree: Doctor of Engineering, Tokyo Univ. of Sci., 1999, Title of the Thesis: Design and analysis of randomized clinical trials with recurrent events. Employment: 1993.4-1995.3, Biostatistician, Rhone-Poulenc Rorer, Inc. 1998.4-2001.3, Research Associate, Department of Health Sciences, Oita University 2001.4-2002.4, Assistant Professor, Department of Health Sciences, Oita University 2002.5-2008.6, Associate Professor, Department of Pharmacoepidemiology, Kyoto 2008.7-2009.9, Associate Professor, Department of Data Science, The Institute of 2009.10-2013.3, Professor, Department of Data Science, The Institute of Statistical 2013.4-present, Professor, Department of Biostatistics, Nagoya University Graduate Research Themes: Design and analysis of clinical studies, Analysis of genomic data Research on biostatistical methodologies: 1. Matsui S, Ohashi Y. (1999). Analysis of recurrent events: Application to a clinical trial of colony stimulating factor with the endpoint of febrile neutropenia. Statistics in Medicine, 18, 2. Matsui S, Miyagishi H. (1999). Design of clinical trials for recurrent events with periodic monitoring. Statistics in Medicine, 18, 3005-3020. 3. Matsui S. (2004). Analysis of times to repeated events in two-arm randomized trials with noncompliance and early withdrawal. Biometrics, 60, 965-976. 4. Matsui S. (2005). Sample size calculations for comparative clinical trials with over-dispersed Poisson process data. Statistics in Medicine, 24, 1339-1356. 5. Matsui S. (2005). Stratified analysis in randomized trials with noncompliance. Biometrics, 61, 6. Matsui S. (2006). Reducing false positive findings in statistical analysis of pharmacogenomic biomarker studies using high-throughput technologies. Current Drug Safety, 1, 135-141. 7. Matsui S. (2006). Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays. BMC Bioinformatics, 7, 156. 8. Matsui S, Ito M, Nishiyama H, Uno H, Kotani H, Watanabe J, Guilford P, Reeve A, Fukushima M, Ogawa O. (2007). Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models. Bioinformatics, 23, 732-738. 9. Matsui S, Zeng S, Yamanaka T, Shaughnessy J. (2008). Sample size calculations based on ranking and selection in microarray experiments. Biometrics, 64, 217-226. 10. Matsui S, Yamanaka T, Barlogie B, Shaughnessy J, Crowley J. (2008). Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma. Statistics in Medicine, 27, 1106-1120. 11. Matsui S, Oura T. (2009). Sample sizes for a robust ranking and selection of genes in microarray experiments. Statistics in Medicine, 28, 2801-2816. 12. Oura T, Matsui S, Kawakami K. (2009). Sample size calculations for controlling the distribution of false discovery proportion in microarray experiments. Biostatistics, 10, 694-705. 13. Noma H, Matsui S, Omori T, Sato T. (2010). Bayesian ranking and selection methods using hierarchical mixture models in microarray studies. Biostatistics, 11, 281-289. 14. Noma H, Matsui S. (2010). Optimality of gene ranking based on univariate P-values for detecting differentially expressed genes. Japanese Journal of Biometrics, 31, 13-21. 15. Matsui S, Noma H. (2011). Estimation and selection in high-dimensional genomic studies for developing molecular diagnostics. Biostatistics, 12, 223-233. 16. Matsui S, Noma H. (2011). Estimating effect sizes of differentially expressed genes for power and sample size assessments in microarray experiments. Biometrics, 67, 1225-1235. 17. Noma H, Matsui S. (2012). The optimal discovery procedure in multiple significance testing: an empirical Bayes approach. Statistics in Medicine, 31, 165-176. 18. Matsui S, Simon R, Qu P, Shaughnessy J, Barlogie B, Crowley J. (2012). Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. Clinical Cancer Research, 18, 6065-6073. 19. Noma H, Matsui S. (2013). Empirical Bayes ranking and selection methods via semiparametric hierarchical mixture models in microarray studies. Statistics in Medicine, 32, 1904-1916. 20. Mori K, Oura T, Noma H, Matsui S. (2013). Cancer outlier analysis based on mixture modeling of gene expression data. Computational and Mathematical Methods in Medicine, Article ID: 21. Noma H, Matsui S. (2013). An empirical Bayes optimal discovery procedure based on semiparametric hierarchical mixture models. Computational and Mathematical Methods in 22. Matsui S. (2013). Genomic biomarkers for personalized medicine: development and validation in clinical studies. Computational and Mathematical Methods in Medicine, Article ID: 865980. 23. Shinohara M, Toyokuni S, Morimoto T, Matsui S, Honjo T, Shinohara T. (2003). Functional assessment of self-renewal activity of male germline stem cells following cytotoxic damage and serial transplantation. Biology of Reproduction, 68, 1801-1807. 24. Matsui S, Sadaike T, Hamada C, Fukushima M. (2005). Creutzfeldt-Jakob disease and cadaveric dura mater grafts in Japan: an updated analysis of incubation time. Neuroepidemiology, 24, 25. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. (2005). Prognostic factor analysis for plaque psoriasis. Dermatology, 211, 103-106. 26. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H. (2005). Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. New England Journal of 27. Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S. (2005). Erythropoietin as a retinal angiogenic factor. New England Journal of Medicine, 353, 2190-2191; author reply 28. Nishimura T, Tada H, Nakagawa M, Teramukai S, Matsui S, Fukushima M. (2006). Lessons from gefitinib-induced interstitial lung disease in Japan and proposal for the prevention of serious drug-induced suffering: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharmacy Practice, 4, 168-178. 29. Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford P, Reeve A, Ogawa O. (2007). P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. Journal of Urology, 178, 1073-1079. 30. Tada H, Matsui S, Kawahara M, Hosoe S, Hamada C, Fukushima M. (2008). Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small cell lung cancer: Single institution experience. European Journal of Cancer Care, 17, 120-126. 31. Tsubouchi M, Morishita R, Tabata Y, Matsui S, Kawakami K. (2008). Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan. Regenerative Medicine, 3, 497-504. 32. Tsubouchi M, Matsui S, Banno Y, Kurokawa K, Kawakami K. (2008). Overview of the clinical application of regenerative medicine products in Japan. Health Policy, 88, 62-72. 33. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y. (2008). Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. Journal of Atherosclerosis Thrombosis, 15, 292-303. 34. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK, Konishi I. (2010). Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene, 29, 1741-1752. 35. Yoshimura K, Kamoto T, Ogawa O, Matsui S, Tsuchiya N, Tada H, Murata K, Yoshimura K, Habuchi T, Fukushima M. (2010). Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: An open-label study. International Journal of Urology, 17, 36. Matsumura N, Mandai M, Okamoto T, Yamaguchi K, Yamamura S, Oura T, Baba T, Hamanishi J, Kang HS, Matsui S, Mori S, Murphy SK, Konishi I. (2010). Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Science, 101, 2658-2663. 37. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, Mizokami Y, Chiba T, Matsui S, Kanto T, Shimada K, Uchiyama S, Uemura N, Hiramatsu N. for the Lansoprazole Ulcer Prevention Study Group (Low-Dose Aspirin Therapy). (2011). Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: Results of a prospective, multicenter, double-blind, randomized, double-dummy, active-control trial. Journal of Gastoroenterogy, 46, 724-735. 38. Shoji S, Suzuki M, Tomono Y, Bockbrader HN, Matsui S. (2011). Population pharmacokinetics of pregabalin in healthy subjects and patients with postherpetic neuralgia or diabetic peripheral neuropathy. British Journal of Clinical Pharmacology, 72, 63-76. 39. Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S, Kanto T, Soen S, Takeuchi T, Hiraishi H, Hiramatsu N. (2012). Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: Results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. Journal of Gastroenterology, 47, 540-552. 40. Negoro H, Kanematsu A, Doi M, Suadicani SO, Matsuo M, Imamura M, Okinami T, Nishikawa N, Oura T, Matsui S, Seo K, Tainaka M, Urabe S, Kiyokage E, Todo T, Okamura H, Tabata Y, Ogawa O. (2012). Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm. Nature Communications, 3: 809. 41. Ishiguro M, Mochizuki H, Tomita N, Shimada Y, Takahashi K, Kotake K, Watanabe M, Kanemitsu Y, Ueno H, Ishikawa T, Uetake H, Matsui S, Teramukai S, Sugihara K. (2012). Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer. BMC Cancer, 12:281. 42. Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S, Kanto T, Hiraishi H, Hiramatsu N, Sugano K. (2012). Endoscopic evaluation of non-steroidal anti-inflammatory drug (NSAID)-induced gastric and duodenal ulcers during prophylaxis with lansoprazole. Journal of Gastroenterology and Hepatology Research, 1, 260-265. 43. Kokubo T, Matsui S, Ishiguro M. (2013). Meta-analysis of oro-cecal transit time in fasting subjects. Pharmaceutical Research, 30, 402-411. 44. Atagi S, Katakami N, Yoshioka H, Fukuoka M, Kudoh S, Ogiwara A, Imai M, Ueda M, Matsui S. (2013). Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase 4 study (JO21661). Clinical Lung Cancer, 14, 407-417. 45. Tsuchiya N, Matsui S, Narita S, Kamba T, Mitsuzuka K, Hatakeyama S, Horikawa Y, Inoue T, Saito S, Ohyama C, Arai Y, Ogawa O, Habuchi T. (2013). Distinct cancer-specific survival in metastatic prostate cancer patients classified by a panel of single nucleotide polymorphisms of cancer-associated genes. Genes & Cancer (In press). 1. Matsui S. (2006). Statistical applications using DNA microarrays for cancer diagnosis and prognosis, Handbook of Statistics in Clinical Oncology, 2nd edn. (eds J.J. Crowley and D.P. 2. Matsui S, Noma H. (2012). Analysis of DNA microarrays, Handbook of Statistics in Clinical Oncology, 3rd edn. (eds JJ. Crowley and A Hoering), CRC Press, Boca Raton. 3. Noma H, Matsui S. (2012). Bayesian Ranking and Selection Methods in Microarray Studies, Statistical Diagnostics for Cancer. (eds M. Dehmer and F. Emmert-Streib), Wiley. 4. Matsui S, Nonaka T, Choai Y. (2013). Design of phase III clinical trials with predictive biomarkers for personalized medicine. Developments in Statistical Evaluation of Clinical Trials, 5. Hirakawa A, Matsui S. (2013). Dose-finding for two-agent combination phase I trials. Developments in Statistical Evaluation of Clinical Trials, Springer. (In press) 6. Matsui S, Buyse M, Simon R. Design and Analysis of Clinical Trials for Predictive Medicine. International Biometric Society, American Statistical Association, Japan Statistical Society, The Biometric Society of Japan, Japanese Society of Applied Statistics, Visiting Researcher, Translational Research Informatics Center, Foundation for Biomedical Research and Innovation (2002-present) The International Biometric Society, Representative Council Member (2011-2014), Current Drug Safety Editorial Board (2005-present) Japanese Journal of Clinical Oncology Review Board (2005-present) The Biometric Society of Japan, Director (2007-2014) Japanese Journal of Biometrics, Editor-in-chief (2009-2014)

Source: http://www.nagoya-biostat.jp/assets/files/english/Shigeyuki_MATSUI.pdf

[courrier - 30] courrier/courrier<pag30-31> . 30-09-05

Prevenir a pandemia Um negócio de milhões A ameaça estendeu-se ao homem e fez do medicamento para a gripeTamiflu uma mina de ouro para o gigante farmacêutico Roche H Á dias estive em Washington e mentar da NATO sobre a preparaçãoda segurança civil em caso de ata- as pessoas queiram comprar os nossos produtos e o mes- mo se aplica ao Tamiflu.» «Claro. Por isso,

Microsoft word - 1980.276

Bramford to Twinstead Tee Connection Project Notes to accompany Biodiversity baseline information The biodiversity information consists of two sets of plans. The first set of plans (G1980.297d – 302d) illustrates the findings of the habitat survey work undertaken by TEP along the preferred route corridor. This survey has been carried out using a combination of access to land (where this has b

Copyright © 2010-2014 Pdf Medic Finder